MA47215A - Procédés prédictifs et diagnostiques pour le cancer de la prostate - Google Patents

Procédés prédictifs et diagnostiques pour le cancer de la prostate

Info

Publication number
MA47215A
MA47215A MA047215A MA47215A MA47215A MA 47215 A MA47215 A MA 47215A MA 047215 A MA047215 A MA 047215A MA 47215 A MA47215 A MA 47215A MA 47215 A MA47215 A MA 47215A
Authority
MA
Morocco
Prior art keywords
predictive
prostate cancer
diagnostic procedures
diagnostic
procedures
Prior art date
Application number
MA047215A
Other languages
English (en)
Inventor
Krishnan Nandabalan
Luca Rastelli
Original Assignee
Bioxcel Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioxcel Therapeutics Inc filed Critical Bioxcel Therapeutics Inc
Publication of MA47215A publication Critical patent/MA47215A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Medical Informatics (AREA)
  • Theoretical Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MA047215A 2017-01-09 2018-01-09 Procédés prédictifs et diagnostiques pour le cancer de la prostate MA47215A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762443831P 2017-01-09 2017-01-09
US201762473507P 2017-03-20 2017-03-20
US201762561218P 2017-09-21 2017-09-21

Publications (1)

Publication Number Publication Date
MA47215A true MA47215A (fr) 2019-11-13

Family

ID=62791142

Family Applications (1)

Application Number Title Priority Date Filing Date
MA047215A MA47215A (fr) 2017-01-09 2018-01-09 Procédés prédictifs et diagnostiques pour le cancer de la prostate

Country Status (4)

Country Link
US (2) US11613785B2 (fr)
EP (1) EP3565560B1 (fr)
MA (1) MA47215A (fr)
WO (1) WO2018129497A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108136025B (zh) 2015-07-16 2022-09-06 比奥克斯塞尔医疗股份有限公司 一种使用免疫调节治疗癌症的新颖方法
MA47215A (fr) 2017-01-09 2019-11-13 Bioxcel Therapeutics Inc Procédés prédictifs et diagnostiques pour le cancer de la prostate
AU2019396206A1 (en) * 2018-12-10 2021-06-17 Bioxcel Therapeutics, Inc. Novel approach for treatment of cancer using immunomodulation
US20220025061A1 (en) * 2018-12-10 2022-01-27 Bioxcel Therapeutics, Inc. Combination therapies for treating disease using an innate immunity modifier and an ox40 agonist
WO2024097856A1 (fr) * 2022-11-03 2024-05-10 Onkosxcel Therapeutics, Llc Biomarqueurs prédictifs pour la réactivité à des inhibiteurs de dpp dans des cancers

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
DE69330523T4 (de) 1992-08-21 2012-08-23 Vrije Universiteit Brussel Immunoglobuline ohne leichte ketten
US6838254B1 (en) 1993-04-29 2005-01-04 Conopco, Inc. Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of camelidae
JP4748908B2 (ja) 1999-09-10 2011-08-17 ザ・ユニバーシティ・オブ・シドニー ジペプチジルペプチダーゼ
EP1268550A2 (fr) 2000-03-17 2003-01-02 Boehringer Ingelheim Pharma KG Anticorps humains specifiques de fap-alpha
GB0027552D0 (en) 2000-11-10 2000-12-27 Boehringer Ingelheim Pharma Anti-tumor compounds
EP1576014B1 (fr) 2002-12-23 2011-06-29 Wyeth LLC Anticorps anti pd-1 et leurs utilisations
KR101339628B1 (ko) 2005-05-09 2013-12-09 메다렉스, 인코포레이티드 예정 사멸 인자 1(ｐｄ-1)에 대한 인간 모노클로날 항체, 및 항-ｐｄ-1 항체를 단독 사용하거나 기타 면역 요법제와 병용한 암 치료 방법
EP1943257A2 (fr) 2005-05-19 2008-07-16 Genentech, Inc. Composes inhibiteurs de proteines d'activation de fibroblastes et procedes
KR101888321B1 (ko) 2005-07-01 2018-08-13 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
EP1898899A4 (fr) 2005-07-05 2009-07-29 Tufts College Inhibiteurs de proteine alpha d'activation des fibroblastes
EP1760076A1 (fr) 2005-09-02 2007-03-07 Ferring B.V. Inhibiteur de FAP
EP1806365A1 (fr) 2006-01-05 2007-07-11 Boehringer Ingelheim International GmbH Anticorps spécifiques pour la protéine alpha d'activation de fibroblastes et leurs immunoconjugués
EP2262837A4 (fr) 2008-03-12 2011-04-06 Merck Sharp & Dohme Protéines de liaison avec pd-1
PL2350129T3 (pl) 2008-08-25 2015-12-31 Amplimmune Inc Kompozycje antagonistów PD-1 i sposoby stosowania
CA2735006A1 (fr) 2008-08-25 2010-03-11 Amplimmune, Inc. Antagonistes de pd-1 et leurs procedes d'utilisation
CN102203061A (zh) 2008-09-25 2011-09-28 分子制药洞察公司 选择性seprase抑制剂
KR20210060670A (ko) 2008-12-09 2021-05-26 제넨테크, 인크. 항-ｐｄ-ｌ１ 항체 및 ｔ 세포 기능을 향상시키기 위한 그의 용도
EP2389176A4 (fr) 2009-01-23 2012-08-01 Univ Sydney Nouvelle thérapie pour maladie métabolique
US8345509B2 (en) 2009-04-16 2013-01-01 Chevron U.S.A., Inc. System and method to create three-dimensional images of non-linear acoustic properties in a region remote from a borehole
CA2773515C (fr) 2009-09-29 2015-04-28 Roche Glycart Ag Anticorps agonistes bispecifiques du recepteur de mort
EP2483316A1 (fr) 2009-10-02 2012-08-08 Ludwig Institute for Cancer Research Ltd. Anticorps dirigés contre la protéine d'activation du fibroblaste, et utilisations et procédés correspondants
WO2011066389A1 (fr) 2009-11-24 2011-06-03 Medimmmune, Limited Agents de liaison ciblés dirigés contre b7-h1
US20130017199A1 (en) 2009-11-24 2013-01-17 AMPLIMMUNE ,Inc. a corporation Simultaneous inhibition of pd-l1/pd-l2
MA34519B1 (fr) 2010-08-13 2013-09-02 Roche Glycart Ag Anticorps anti-fap et procédés d'utilisation
US20120213781A1 (en) 2011-02-11 2012-08-23 Zyngenia, Inc. Monovalent and Multivalent Multispecific Complexes and Uses Thereof
CA2846852C (fr) 2011-08-30 2021-01-12 Trustees Of Tufts College Inhibiteurs de proteasome actives par fap utilises pour traiter les tumeurs solides
CA2856895C (fr) 2011-11-28 2021-10-26 Merck Patent Gmbh Anticorps anti-pd-l1 et utilisations associees
US9346814B2 (en) 2012-01-17 2016-05-24 Universiteit Antwerp FAP inhibitors
US9365641B2 (en) 2012-10-01 2016-06-14 The Trustees Of The University Of Pennsylvania Compositions and methods for targeting stromal cells for the treatment of cancer
US9593148B2 (en) 2012-11-02 2017-03-14 Georg-August-Universitat Gottingen Stiftung Offentlichen Rechts DPP8 and DPP9 peptide inhibitors
UA118028C2 (uk) 2013-04-03 2018-11-12 Рош Глікарт Аг Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування
KR20160081898A (ko) 2013-09-06 2016-07-08 오리진 디스커버리 테크놀로지스 리미티드 면역조절제로서 1,3,4-옥사디아졸 및 1,3,4-티아디아졸 유도체
SG11201601682RA (en) 2013-09-06 2016-04-28 Aurigene Discovery Tech Ltd 1,2,4-oxadiazole derivatives as immunomodulators
CN108136025B (zh) 2015-07-16 2022-09-06 比奥克斯塞尔医疗股份有限公司 一种使用免疫调节治疗癌症的新颖方法
MA47215A (fr) 2017-01-09 2019-11-13 Bioxcel Therapeutics Inc Procédés prédictifs et diagnostiques pour le cancer de la prostate

Also Published As

Publication number Publication date
WO2018129497A1 (fr) 2018-07-12
EP3565560A1 (fr) 2019-11-13
US20230227918A1 (en) 2023-07-20
EP3565560B1 (fr) 2024-05-29
US20210355541A1 (en) 2021-11-18
EP3565560A4 (fr) 2021-01-13
US11613785B2 (en) 2023-03-28

Similar Documents

Publication Publication Date Title
IL271888A (en) Therapeutic and diagnostic methods for cancer
IL265759A (en) Therapeutic and diagnostic methods for cancer
IL268396A (en) Diagnostic and therapeutic methods for cancer
IL261422A (en) Therapeutic and diagnostic methods for cancer
IL274246A (en) Methods for diagnosing and treating cancer
MA47215A (fr) Procédés prédictifs et diagnostiques pour le cancer de la prostate
IL264674B1 (en) Antibodies to siglec7 for cancer treatment
MA42238A (fr) Procédés de diagnostic du cancer de la vessie
IL262208A (en) Diagnostic and therapeutic methods for cancer
IL273071A (en) Treatment and diagnosis methods for cancer
IL258378B (en) Inhibitors of 18f-labeled prostate-specific membrane antigen and their use as imaging agents for prostate cancer
MA46927A (fr) Procédés de détection du cancer
IL263562A (en) Methods and compositions for prostate cancer diagnosis and treatment
ZA202000851B (en) Antibodies useful in cancer diagnosis
HK1243434A1 (zh) Igf-1r抗體及其診斷癌症的用途
GB201619808D0 (en) Biomarkers for the prognosis and diagnosis of cancer
DK3526347T3 (da) Indolamin-2,3-dioxygenase-analyse til diagnose og prognose af prostatacancer
IL280421A (en) Cancer treatment by antibody
ITUA20161418A1 (it) Biomarcatori urinari per la diagnosi del carcinoma della prostata
GB201917428D0 (en) Prostate cancer diagnostic
HK1248730A1 (zh) Igf-1r抗體及其用於癌症診斷的用途
GB201813138D0 (en) Cancer treatment with an antibody
SG11201911602RA (en) 18f-labelled compound for prostate cancer diagnosis, and use thereof